Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: A north American brain tumor consortium study Academic Article uri icon

Overview

MeSH Major

  • Anticonvulsants
  • Antineoplastic Combined Chemotherapy Protocols
  • Brain Neoplasms
  • Glioma

abstract

  • The recommended phase II dose of irinotecan in combination with temozolomide for patients receiving EIAEDs is 500 mg/m(2), administrated every 15 days on a 28-day schedule. This study also confirmed that concomitant administration of EIAEDs increases irinotecan clearance and influences SN-38 disposition. No pharmacokinetic interaction was observed between temozolomide and irinotecan.

publication date

  • December 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4802002

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-07-0874

PubMed ID

  • 18056194

Additional Document Info

start page

  • 7133

end page

  • 8

volume

  • 13

number

  • 23